568 related articles for article (PubMed ID: 8653704)
1. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of S-1 on DMH induced colon cancer in rats.
Tsunoda A; Shibusawa M; Tsunoda Y; Yokoyama N; Nakao K; Kusano M; Nomura N; Nagayama S; Takechi T
Anticancer Res; 1998; 18(2A):1137-41. PubMed ID: 9615778
[TBL] [Abstract][Full Text] [Related]
3. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
[TBL] [Abstract][Full Text] [Related]
6. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
7. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma.
Konno H; Tanaka T; Baba M; Kanai T; Matsumoto K; Kamiya K; Nakamura S
Jpn J Cancer Res; 1999 Apr; 90(4):448-53. PubMed ID: 10363584
[TBL] [Abstract][Full Text] [Related]
10. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of UFT on postoperative lung metastasis of mammary adenocarcinoma in SHR rats].
Komatsumoto M; Li S; Hamada J; Takeichi N; Hosokawa M; Okayasu T; Tanabe T; Kobayashi H
Gan To Kagaku Ryoho; 1988 May; 15(5):1739-45. PubMed ID: 3130810
[TBL] [Abstract][Full Text] [Related]
12. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
14. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Nukatsuka M; Fujioka A; Nakagawa F; Oshimo H; Kitazato K; Uchida J; Sugimoto Y; Nagayama S; Fukushima M
Int J Oncol; 2004 Dec; 25(6):1531-6. PubMed ID: 15547687
[TBL] [Abstract][Full Text] [Related]
15. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
16. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T
Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Tachimori A; Yamada N; Amano R; Ohira M; Hirakawa K
Anticancer Res; 2008; 28(2A):629-38. PubMed ID: 18507001
[TBL] [Abstract][Full Text] [Related]
19. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
Sekiguchi I; Suzuki M; Tamada T; Nishida M
Gan To Kagaku Ryoho; 1985 May; 12(5):1094-8. PubMed ID: 3922312
[TBL] [Abstract][Full Text] [Related]
20. [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
Futami K; Arima S; Yoshimura S; Okamoto T; Yamasaki K; Koto T; Yamasaki S; Kawahara K; Ikuno T
Gan To Kagaku Ryoho; 1991 Feb; 18(2):215-20. PubMed ID: 1992915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
